title: Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.
abstract: OBJECTIVE
  The aim of this study was to assess the effect of treatment with a St. John's wort product (Movina) on cholesterol [total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol] and triglyceride levels in patients with hypercholesterolemia on treatment with a stable dose of atorvastatin in a controlled, randomised, open, crossover interaction study.
  
  
  METHODS
  Sixteen patients with hypercholesterolemia treated with a stable dose of atorvastatin (10-40 mg/daily) for at least 3 months were treated with Movina one tablet (containing 300 mg of hypericum perforatum) twice daily and control (a commercially available multivitamin tablet Vitamineral). After a run-in period of 4 weeks, patients were randomised to treatment with either Movina or control for 4 weeks in a crossover design. The atorvastatin dose was kept unchanged during the study period (12 weeks), and assessments of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were performed in the morning with the patients in the fasting condition. The difference between control and active treatment in LDL cholesterol after 4 weeks of treatment was the primary endpoint.
  
  
  RESULTS
  All patients completed the study. The St. John's wort product significantly increased the serum level of LDL cholesterol compared with control (2.66 mmol/l compared with 2.34 mmol/l, p = 0.004). A significant increase in total cholesterol was also observed (5,10 mmol/l compared with 4.78 mmol/l, p = 0.02). No statistically significant change was observed in HDL cholesterol (1.59 mmol/l and 1.56 mmol/l, p = 0.49) or in triglycerides (1.87 mmol/l and 1.94 mmol/l, p = 0.60). No product-related side effects were reported
  
  
  CONCLUSIONS
  An interaction was observed between the studied St.-John's-wort-containing product and atorvastatin. Physicians and patients should be aware of this interaction and if treatment with a St. John's wort product is considered necessary, then there may be a need for increasing the dose of atorvastatin.
authors: Department of Medicine/Clinical Pharmacology, Gothenburg University, Sahlgrenska University Hospital, Vita Stråket 11, S-413 45, Gothenburg, Sweden. lennart.andren@pharm.gu.se
authors: L
authors: L
authors: Andrén
authors: A
authors: A
authors: Andreasson
authors: R
authors: R
authors: Eggertsen
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis; D000368:Aged; D000069059:Atorvastatin; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D018592:Cross-Over Studies; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis; D004790:Enzyme Induction; D005260:Female; D006538:Heptanoic Acids / Q000493:pharmacokinetics / Q000627:therapeutic use*; D041743:Herb-Drug Interactions; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D020902:Hypericum; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects* / Q000201:enzymology; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D028321:Plant Preparations / Q000494:pharmacology*; D011758:Pyrroles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D015854:Up-Regulation
chemical_list: C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D028321:Plant Preparations; D011758:Pyrroles; D014280:Triglycerides; D003577:Cytochrome P-450 Enzyme System; D002784:Cholesterol; D000069059:Atorvastatin; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human
references: Complement Ther Med. 2001 Mar;9(1):2-11
references: 11264963
references: JAMA. 2004 Mar 3;291(9):1071-80
references: 14996776
references: Clin Pharmacol Ther. 2001 Dec;70(6):518-24
references: 11753267
references: JAMA. 2002 Dec 18;288(23):2998-3007
references: 12479764
references: N Engl J Med. 2005 Apr 7;352(14):1425-35
references: 15755765
references: Drugs. 2004;64 Suppl 2:43-60
references: 15765890
references: Lancet. 2000 Feb 12;355(9203):548-9
references: 10683008
references: BMJ. 2004 Jul 3;329(7456):27-30
references: 15231618
references: Clin Pharmacol Ther. 2000 Dec;68(6):598-604
references: 11180019
references: Pharmacotherapy. 2006 Nov;26(11):1601-7
references: 17064205
references: JAMA. 2003 Sep 17;290(11):1500-4
references: 13129991
references: J Clin Psychopharmacol. 2002 Feb;22(1):46-54
references: 11799342
references: Pharmacol Ther. 2006 Oct;112(1):71-105
references: 16714062
references: Lancet. 2000 Feb 12;355(9203):547-8
references: 10683007